Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy

Stephen A. Klassen, PhD[1#], Jonathon W. Senefeld, PhD[1#], Patrick W. Johnson, MSc[2], Rickey E. Carter, PhD[2], Chad C. Wiggins, PhD[1], Shmuel Shoham, MD[3], Brenda J. Grossman, MD[4], Jeffrey P. Henderson, MD, PhD[5,6], James Musser, MD, PhD[7,8,9], Eric Salazar, MD, PhD[7,9], William R. Hartman, MD[10], Nicole M. Bouvier, MD[11,12], Sean T. H. Liu, MD, PhD[11,12], Liise-anne Pirofski, MD[13], Sarah E. Baker, PhD[1], Noud van Helmond, MD[14], R. Scott Wright, MD[15,16], DeLisa Fairweather, PhD[17], Katelyn A. Bruno, PhD[17], Zhen Wang, PhD[18], Nigel S. Paneth, MD[19,20], Arturo Casadevall, MD, PhD[21 †], and Michael J. Joyner, MD[1 †*]

Affiliations:
[1]Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota,
[2]Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida,
[3]Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland,
[4]Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri,
[5]Division of Infectious Diseases, Department of Medicine and [6]Department of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
[7]Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas
[8]Center for Molecular and Translational Human Infectious Diseases, Houston Methodist Research Institute, Houston, Texas
[9]Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York
[10]Department of Anesthesiology, University of Wisconsin-Madison School of Medicine and Public Health
[11]Division of Infectious Diseases, Department of Medicine and [12]Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York
[13]Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York
[14]Department of Anesthesiology, Cooper Medical School of Rowan University, Cooper University Health Care, Camden, New Jersey
[15]Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
[16]Director Human Research Protection Program, Mayo Clinic, Rochester, Minnesota
[17]Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida
[18]Evidence-Based Practice Center, Robert D. and Patricia E. Kern Center for Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota
[19]Department of Epidemiology and Biostatistics and [20]Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, East Lansing, Michigan
[21]Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

[#] S.A.K. and J.W.S. contributed equally to this work
[†] A.C. and M.J.J. are co-senior authors

*Correspondence:
Michael J. Joyner, M.D., Department of Anesthesiology and Perioperative Medicine
Mayo Clinic **|** 200 First Street SW **|** Rochester, MN 55905
joyner.michael@mayo.edu **|** 507-255-7197

Abstract

To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from randomized clinical trials (RCT), matched-control, case series, and case report studies. Random-effects analyses of RCT data demonstrated that hospitalized COVID-19 patients transfused with convalescent plasma exhibited a lower mortality rate compared to patients receiving standard treatments. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients.

Introduction

Convalescent plasma is a century-old passive antibody therapy that has been used to treat outbreaks of novel infectious diseases, including those affecting the respiratory system.[1,2] Due to the lack of vaccines or approved monoclonal antibody therapies, human convalescent plasma is currently being used word-wide to treat coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[2–5] However, evidence for therapeutic COVID-19 convalescent plasma efficacy still requires definitive support from large randomized clinical trials (RCT). As a result, there remains a lack of consensus on convalescent plasma use in hospitalized COVID-19 patients.[6] Smaller RCTs, matched-control studies, and case series studies investigating convalescent plasma therapy for COVID-19 have emerged and provided a positive efficacy signal.[7–13] Most of these studies, however, lacked appropriate statistical power or were terminated early.

There is an urgent need to determine the efficacy of potential treatments amidst the ongoing COVID-19 pandemic. Although a 'living' systematic review has summarized a broad-ranging clinical experience with convalescent plasma,[6] this approach may be limited because: i) it examined a breadth of clinical variables, ii) it has been outpaced by the publication rate of convalescent plasma studies, and iii) it employed stringent inclusion criteria for aggregating patient outcomes, which prevented a preliminary assessment of convalescent plasma efficacy. Given the insufficient patient outcome data available from RCTs, we used a practical approach with less stringent criteria for study selection to pool COVID-19 clinical outcomes, focusing solely on mortality data from RCTs, matched-control, and case series or case report studies in real time. Our primary objective was to derive an aggregate estimate of mortality rates from transfused (case) and non-transfused (control) cohorts of contemporaneous COVID-19 studies.

Methods

Studies published on pre-print servers or peer-reviewed journals that investigated human convalescent plasma therapy among hospitalized COVID-19 patients were identified from a search of the online PubMed database from January 1, 2020 through October 27, 2020. Keywords used in the search included: ((convalescent plasma) OR (convalescent serum)) AND COVID-19 using the following limits: Humans. The references of all eligible studies were also reviewed to identify other potentially eligible studies. In order to be considered eligible for inclusion, studies must have: 1) included hospitalized patients with COVID-19, 2) used convalescent plasma treatment, and 3) reported mortality. Mortality rates were calculated at the longest reported vital status for each study and ORs were aggregated across the included studies using the DerSimonian–Laird random-effects method.[14] Simple random-effects meta-regression analyses evaluated the moderator variables (i.e., cohort age, proportion of cohort receiving mechanical ventilation, and duration of study follow up) on mortality for all clinical studies. All analyses were performed with Comprehensive Meta-analysis Software (Biostat, version 3.3.070). Tests were two-tailed and alpha was 0.05.

Results and Discussion

The literature search yielded 171 studies, of which 38 studies met the eligibility criteria. The present analyses included a total of eighteen clinical trials including five RCTs,[7,8,12,13,15] thirteen matched-control studies,[11,16,25–27,17–24] and twenty case series or case reports[10,28,37–46,29–36] containing 10,436 COVID-19 patient outcomes from around the world (**Table 1 and Table 2**). The age of patients enrolled in these studies ranged from 24 to 100 years, with a greater proportion of men than women in most studies (proportion of women: 0% to 100%) (**Supplemental Table 1**). All studies included patients with severe or life-threatening COVID-19.

At the time of plasma transfusion, the proportion of patients on mechanical ventilation varied by study from 0% to 100%. The duration of follow up ranged from 7 to 60 days (**Supplemental Table 1**). In all studies, patients were eligible to receive concomitant and experimental therapies such as antivirals, steroids, and chloroquine or hydroxychloroquine.

When data from the five RCTs were aggregated, there was no association between convalescent plasma therapy and mortality (odds ratio [OR]: 0.58, 95% confidence interval [95% CI]: 0.29, 1.15, $P = 0.12$, $I^2 = 42\%$) (**Table 1 and Figure 1**). Although the heterogeneity was low, one RCT (Agarwal et al.[15]) demonstrated a directionally different effect, had a large statistical weight (**Supplemental Table 2**), and represented the primary source of heterogeneity ($\Delta I^2 = 42\%$). Additionally, in the context of COVID-19, neutralizing antibodies are anticipated to be the primary active agent in convalescent plasma and the marker of plasma potency.[47,48] In this regard, two studies report a dose-response relationship between convalescent plasma antibody level and mortality, suggesting the need for a sufficient amount of antibody for therapeutic success.[47,48] The Agarwal et al.[15] trial included a large proportion of patients (~70%) in the convalescent plasma arm whom received plasma with low levels of SARS-CoV-2 antibodies less than 1:80, with ~30% receiving plasma with no detectable antibodies.[15] Thus, there were strong analytical and biological rationales to exclude this study from statistical models.

When analyses were performed on RCT data excluding the Agarwal et al.[15] study, patients transfused with convalescent plasma exhibited a lower mortality rate compared to non-transfused COVID-19 patients (10% vs. 21% mortality; OR: 0.43, 95% CI: 0.22, 0.84, $P = 0.01$, $I^2 = 0\%$) (**Table 1 and Figure 1**). The aggregate OR (0.43) indicates that convalescent plasma was associated with a 57% reduction in the odds of mortality among hospitalized COVID-19 patients.

Similarly, when we aggregated mortality data from the thirteen matched-control studies, patients transfused with convalescent plasma exhibited a lower mortality rate compared to non-transfused patients (20% vs. 29% mortality; OR: 0.50, 95% CI: 0.37, 0.67, $P < 0.001$, $I^2 = 61\%$) (**Table 1 and Figure 1**). One study (Altuntas et al.[27]) represented the entire source of heterogeneity ($\Delta I^2 = 61\%$) among matched-control studies; however, this study was included in subsequent analyses as the OR for pooled matched-control data was similar when excluding the Altuntas et al.[27] study (17% vs. 30% mortality; OR: 0.44, 95% CI: 0.38, 0.51, $P < 0.001$, $I^2 = 0\%$).

Aggregation of mortality data from all clinical trials including RCTs and matched-control trials indicated that patients transfused with convalescent plasma exhibited a 51% reduction in mortality rate compared to patients receiving standard treatments (19% vs. 29% mortality; OR: 0.49, 95% CI: 0.37, 0.64, $P < 0.001$, $I^2 = 53\%$) (**Table 1 and Figure 1**). Simple random-effects meta-regression analyses indicated that cohort age ($P = 0.47$), proportion of cohort receiving mechanical ventilation ($P = 0.07$), and duration of study follow up ($P = 0.79$) did not affect the aggregate OR computed for all clinical trials.

Although the risk of bias is high, the aggregate of available case series or reports demonstrate a mortality rate (14%, range: 0% to 42%) which is similar to the mortality rates exhibited by transfused cohorts from clinical trials (**Table 2**). Three case-series studies explored immunodeficient patients with suppressed antibody production due to hematological malignancies, cancer-directed therapy, or X-linked agammaglobulinemia (XLA) and provided an important 'experiment of nature' to evaluate convalescent plasma efficacy for COVID-19.[35,42,44] For example, Jin et al.[35] highlighted a series of three XLA patients with severe COVID-19 that failed to respond to other supportive treatments but demonstrated strong improvements in

oxygen requirements and viral clearance within days of receiving convalescent plasma transfusions.

This real-time analysis represents the most current aggregation of mortality data from contemporaneous COVID-19 convalescent plasma studies. The aggregate mortality rate of transfused COVID-19 patients was lower than that of non-transfused COVID-19 patients. These results favor the efficacy of convalescent plasma as a COVID-19 therapeutic agent. The primary biological hypothesis for the efficacy of convalescent plasma is antibody-mediated SARS-CoV-2 viral neutralization and interference with viral replication, though other biological mechanisms may also contribute to the mitigation of symptoms.[2] These results align with similar analyses of historical data from convalescent plasma trials for viral diseases such as the 1918 flu epidemic,[1] severe acute respiratory syndrome,[49] and H1N1 influenza.[50] Our findings are discordant with those of a previous 'living' systematic review,[6] which concluded that there was insufficient evidence to determine the impact of convalescent plasma on all-cause mortality based on one prematurely terminated RCT (Li et al.[7]). Using a more practical approach with less stringent study inclusion criteria our analysis comprised 18 clinical trials which all found a directionally similar effect of convalescent plasma and our sub-group analyses based on study design (e.g., RCT and matched-control studies) revealed similar aggregate ORs (**Table 1**).

Mechanistic and clinical data support the reduction in mortality associated with convalescent plasma administration. Importantly, convalescent plasma contains SARS-CoV-2 neutralizing antibodies.[51,52] Convalescent plasma administration increases SARS-CoV-2 clearance in COVID-19 patients[7,16] including immunocompromised individuals,[35,42,53,54] indicating an antiviral effect. Additional evidence arises from animal studies showing that administration of human convalescent plasma is protective against SARS-CoV-2 infection.[55,56] Antibody-mediated interference with viral replication may increase tissue repair and eventually manifest as reduced mortality. In addition, convalescent plasma transfusion is associated with reductions in inflammatory markers, such as chemokines, cytokines and C-reactive protein.[44,57] Concomitant reductions in inflammation and improved gas exchange may underlie the reductions in oxygen requirements associated with convalescent plasma, even in critically ill patients. These findings provide mechanistic evidence for the reduction in mortality observed in patients receiving convalescent plasma.

There are several limitations to this analysis including aggregating mortality data across study populations that varied by: 1) the nation of data origin, 2) timing relative to world-wide progression of the pandemic, 3) clinical diagnostic and treatment algorithms, 4) plasma antibody titer and administration volume, 5) the latency between COVID-19 diagnosis and transfusion, and 6) the duration of follow up after transfusion. While this study did not formally appraise the methodological quality of the included trials, we acknowledge the risk of bias among the present studies, especially non-RCTs.[58,59] However, high-quality evidence from large RCTs remains unavailable and the continuing global health emergency related to COVID-19 necessitated a practical real-time aggregation of existing mortality data. The current findings should be interpreted with the caveat that the analyses excluded one RCT (Agarwal et al.[15]) due to a large statistical weight, a directionally different effect on mortality, and because a large proportion of patients received plasma with low or no detectable antibody levels. Nevertheless, Agarwal et al.[15] did observe a positive effect of convalescent plasma therapy on clinical symptoms and viral clearance.[15] Aggregation of mortality data from all clinical trials including this RCT (Agarwal et al.[15]) provided a similar OR to the overall model (OR: 0.52, 95% CI: 0.40, 0.69, $P < 0.001$, I^2 = 58%). We note that the reports cited in **Table 1** include positive results from different countries, suggesting that efficacy is robust across different health systems. Given the safety of convalescent plasma administration in COVID-19 patients,[3,4] the results of this real-time data

aggregation provide encouragement for its continued use as a therapy and may have broad implications for the treatment of COVID-19 and design of RCTs. Importantly, many of the patients enrolled in the studies included in the present analyses received convalescent plasma transfusions later in their disease course. In this context, prior to antibiotics and effective vaccinations, convalescent plasma therapy was widely understood to be most efficacious very early in the course of hospitalizations.[2,60] As a result, our analysis may underestimate the mortality reduction achievable through early administration of high-titer convalescent plasma for COVID-19.

References

1.   Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann Intern Med*. 2006;145(8):599-609.
2.   Casadevall A, Pirofski L. The convalescent sera option for containing COVID-19. *J Clin Invest*. 2020;130(4):1545-1548.
3.   Joyner MJ, Bruno K, Klassen SA, et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. *Mayo Clin Proc*. 2020;95.
4.   Joyner M, Wright RS, Fairweather D, et al. Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. *J Clin Invest*. Published online 2020.
5.   Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. *J Clin Invest*. Published online 2020.
6.   Piechotta V, Chai KL, Valk SJ, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. *Cochrane Database Syst Rev*. 2020;(7).
7.   Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *JAMA*. Published online 2020.
8.   Gharbharan A, Jordans CCE, GeurtsvanKessel C, et al. Convalescent Plasma for COVID-19. A randomized clinical trial. *medRxiv*. Published online 2020.
9.   Salazar E, Christensen PA, Graviss EA, et al. Treatment of COVID-19 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. *Am J Pathol*. Published online 2020.
10.   Hartman W, Hess AS, Connor JP. Hospitalized COVID-19 patients treated with Convalescent Plasma in a mid-size city in the midwest. *medRxiv*. Published online 2020.
11.   Abolghasemi H, Eshghi P, Cheraghali AM, et al. Clinical Efficacy of Convalescent Plasma for Treatment of COVID-19 Infections: Results of a Multicenter Clinical Study. *Transfus Apher Sci*. Published online 2020:102875.
12.   Rasheed AM, Fatak DF, Hashim HA, et al. The therapeutic potential of Convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. *Le Infez Med*. 2020;28(3):357-366.
13.   Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, et al. Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial. *medRxiv*. Published online 2020.
14.   DerSimonian R, Laird N. Meta-analysis in clinical trials Control Clin Trials. *1986*. 177:10.
15.   Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). *bmj*. 2020;371.
16.   Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci*. 2020;117(17):9490-9496.
17.   Perotti C, Baldanti F, Bruno R, et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial. *medRxiv*. Published online 2020.
18.   Hegerova L, Gooley T, Sweerus KA, et al. Use of Convalescent Plasma in Hospitalized Patients with Covid-19-Case Series. *Blood*. Published online 2020.
19.   Zeng Q-L, Yu Z-J, Gou J-J, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. *J Infect Dis*. 2020;222(1):38-43.
20.   Donato M, Park S, Baker M, et al. Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study. *medRxiv*. Published online 2020.
21.   Liu STH, Lin H-M, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a

propensity score–matched control study. *Nat Med*. Published online 2020:1-6.

22. Salazar E, Christensen PA, Graviss EA, et al. Early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma confirms a signal of significantly decreased mortality. *medRxiv*. Published online 2020.

23. Xia X, Li K, Wu L, et al. Improved Clinical Symptoms and Mortality on Severe/Critical COVID-19 Patients Utilizing Convalescent Plasma Transfusion. *Blood*. Published online 2020.

24. Rogers R, Shehadeh F, Mylona E, et al. Convalescent plasma for patients with severe COVID-19: a matched cohort study. *medRxiv*. Published online 2020.

25. Salazar MR, Gonzalez SE, Regairaz L, et al. EFFECT OF CONVALESCENT PLASMA ON MORTALITY IN PATIENTS WITH COVID-19 PNEUMONIA. *medRxiv*. Published online 2020.

26. Omrani AS, Zaqout A, Baiou A, et al. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report. *J Med Virol*. Published online 2020.

27. Altuntas F, Ata N, Yigenoglu TN, et al. Convalescent plasma therapy in patients with COVID-19. *Transfus Apher Sci*. Published online 2020:102955.

28. Martinez-Resendez MF, Castilleja-Leal F, Torres-Quintanilla A, et al. Initial experience in Mexico with convalescent plasma in COVID-19 patients with severe respiratory failure, a retrospective case series. *medRxiv*. Published online 2020.

29. Jin C, Gu J, Yuan Y, et al. Treatment of 6 COVID-19 Patients with Convalescent Plasma. *medRxiv*. Published online 2020.

30. Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. *J Med Virol*. Published online 2020.

31. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. *Jama*. 2020;323(16):1582-1589.

32. Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. *Chest*. Published online 2020.

33. Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. *J Korean Med Sci*. 2020;35(14).

34. Bobek I, Gopcsa L, Réti M, et al. Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: the first two cases. *Orv Hetil*. 2020;161(27):1111-1121.

35. Jin H, Reed JC, Liu STH, et al. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. *J Allergy Clin Immunol Pract*. Published online 2020.

36. Im JH, Nahm CH, Baek JH, Kwon HY, Lee J-S. Convalescent plasma therapy in coronavirus disease 2019: a case report and suggestions to overcome obstacles. *J Korean Med Sci*. 2020;35(26).

37. Peng H, Gong T, Huang X, et al. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report. *Stem Cell Res Ther*. 2020;11(1):1-6.

38. Xu T, Lin B, Chen C, Liu L, Xue Y. Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report. *Virol J*. 2020;17(1):1-3.

39. Anderson J, Schauer J, Bryant S, Graves CR. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report. *Case Reports Women's Heal*. Published online 2020:e00221.

40.   Bao Y, Lin SY, Cheng ZH, et al. Clinical Features of COVID-19 in a Young Man with Massive Cerebral Hemorrhage—Case Report. *Sn Compr Clin Med*. Published online 2020:1.

41.   Kong Y, Cai C, Ling L, et al. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma. *Transfus Apher Sci*. Published online 2020:102820.

42.   Hueso T, Pouderoux C, Péré H, et al. Convalescent plasma therapy for B-cell depleted patients with protracted COVID-19 disease. *Blood*. Published online 2020.

43.   Olivares-Gazca JC, Priesca-Marín JM, Ojeda-Laguna M, et al. Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study. *Rev Invest Clin*. 2020;72(3):159-164.

44.   Tremblay D, Seah C, Schneider T, et al. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients. *Cancer Med*. Published online 2020.

45.   Çınar OE, Sayınalp B, Karakulak EA, et al. CONVALESCENT (IMMUNE) PLASMA TREATMENT IN A MYELODYSPLASTIC COVID-19 PATIENT WITH DISSEMINATED TUBERCULOSIS. *Transfus Apher Sci*. Published online 2020:102821.

46.   Jamous F, Meyer N, Buus D, et al. Critical Illness Due to Covid-19: A Description of the Surge in a Single Center in Sioux Falls. *South Dakota Med*. 2020;73(7).

47.   US Food and Drug Administration (FDA). Updated Evidence to Support the Emergency Use of COVID-19 Convalescent Plasma (as of 9/23/2020). Published 2020. https://www.fda.gov/media/142386/download

48.   Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. *MedRxiv*. Published online 2020.

49.   Cheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis*. 2005;24(1):44-46.

50.   Hung IFN, To KKW, Lee C-K, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. *Clin Infect Dis*. 2011;52(4):447-456.

51.   Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature [Internet]. 2020.

52.   Klein SL, Pekosz A, Park H-S, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. *J Clin Invest*. Published online 2020.

53.   Mira E, Yarce OA, Ortega C, et al. Rapid recovery of a SARS-CoV-2–infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. *J Allergy Clin Immunol Pract*. 2020;8(8):2793-2795.

54.   Rodriguez Z, Shane AL, Verkerke H, et al. COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease. *Blood Adv*. 2020;4(18):4278.

55.   Imai M, Iwatsuki-Horimoto K, Hatta M, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. *Proc Natl Acad Sci*. 2020;117(28):16587-16595.

56.   Sun J, Zhuang Z, Zheng J, et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. *Cell*. 2020;182(3):734-743.

57.   Bandopadhyay P, D'Rozario R, Lahiri A, et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. *medRxiv*. Published online 2020.

58.   Higgins JPT, Thomas J, Chandler J, et al. *Cochrane Handbook for Systematic Reviews of Interventions*. John Wiley & Sons; 2019.

59.   Reeves BC, Deeks JJ, Higgins JPT, et al. Including non-randomized studies on

intervention effects. *Cochrane Handb Syst Rev Interv*. Published online 2019:595-620.

60.   Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. *Clin Infect Dis*. 1995;21(1):150-161.

Acknowledgements: The authors express their gratitude to convalescent plasma donors.

Author contributions: MJJ, REC, AC, NSP conceived and designed the study. MJJ, SAK, JWS, PWJ, CCW, REC analyzed the data and performed statistical analyses. All authors reviewed, critically revised and approved the final version of the manuscript.

Competing Interests: The authors declare no competing interests.

Data availability: The data supporting the study findings are available within the paper.

Funding: National Heart, Lung, and Blood Institute grant (5R35HL139854, to MJJ), the National Institute of Diabetes and Digestive and Kidney Diseases (5T32DK07352, to JWS and CCW), the Natural Sciences and Engineering Research Council of Canada (PDF-532926-2019, to SAK), the National Institutes of Health (1-F32-HL154320-01 to JWS), the National Institute of Allergy and Infectious Disease (R21 AI145356 and R21 AI152318, to DF; R01 AI1520789, to AC), and the National Heart, Lung, and Blood Institute (R01 HL059842, to AC),

Table 1 | Mortality Rates in Hospitalized COVID-19 Patients

Study	Location	Convalescent Plasma			Control			Statistics		
		Survivor	Non-Survivor	Mortality	Survivor	Non-Survivor	Mortality	OR	P	95% CI
Randomized Clinical Trials										
Avendano-Sola et al.	ESP	38	0	0%	39	4	9%	0.11	0.15	0.01, 2.19
Rasheed et al.	IRQ	20	1	5%	20	8	29%	0.13	0.06	0.01, 1.09
Gharbharan et al.	NLD	37	6	14%	32	11	26%	0.47	0.18	0.16, 1.42
Li et al.	CHN	43	8	16%	38	12	24%	0.59	0.30	0.22, 1.59
Agarwal et al.	IND	201	34	14%	198	31	14%	1.08	0.77	0.64, 1.83
Random Effects Model		339	49	13%	327	66	17%	0.58	0.12	0.29, 1.15
Random Effects Model excluding Agarwal et al.		138	15	10%	129	35	21%	0.43	0.01	0.22, 0.84
Matched-Control Studies										
Duan et al.	CHN	10	0	0%	7	3	30%	0.10	0.15	0.01, 2.28
Perotti et al.	ITA	43	3	7%	16	7	30%	0.16	0.01	0.04, 0.69
Omrani et al.	QAT	39	1	3%	35	5	13%	0.18	0.13	0.02, 1.61
Hegerova et al.	Washington, USA	18	2	10%	14	6	30%	0.26	0.13	0.05, 1.49
Zeng et al.	CHN	1	5	83%	1	14	93%	0.36	0.49	0.02, 6.85
Donato et al.	New York, USA	36	11	23%	775	565	42%	0.42	0.01	0.21, 0.83
Salazar et al.	ARG	647	221	25%	1288	1010	44%	0.44	<0.001	0.37, 0.52
Liu et al.	New York, USA	34	5	13%	118	38	24%	0.46	0.13	0.17, 1.25
Salazar et al.	Texas, USA	301	20	6%	510	72	12%	0.47	<0.001	0.28, 0.79
Xia et al.	CHN	135	3	2%	1371	59	4%	0.52	0.27	0.16, 1.67
Abolghasemi et al.	IRN	98	17	15%	56	18	24%	0.54	0.10	0.26, 1.13
Rogers et al.	Rhode Island, USA	56	8	13%	149	28	16%	0.76	0.52	0.33, 1.77
Altuntas et al.	TUR	669	219	25%	642	246	28%	0.85	0.15	0.69, 1.06
Random Effects Model		2087	515	20%	4340	2071	32%	0.50	<0.001	0.37, 0.67
Overall Random Effects Model [a]		2225	530	19%	5111	2106	29%	0.49	<0.001	0.37, 0.64

CI, confidence interval; OR, odds ratio

[a] random-effects model excludes trial by Agarwal et al.

Table 2 | Mortality Rates in Hospitalized COVID-19 Patients

Study	Location	Convalescent Plasma		
		Survivor	**Non-Survivor**	**Mortality**
Case Series or Reports				
Martinez-Resendez et al.	MEX	8	0	0%
Jin et al.	CHN	6	0	0%
Ye et al.	CHN	6	0	0%
Shen et al.	CHN	5	0	0%
Zhang et al.	CHN	4	0	0%
Ahn et al.	KOR	2	0	0%
Bobek et al.	HUN	2	0	0%
Jin et al.	New York, USA	3	0	0%
Im et al.	KOR	1	0	0%
Peng et al.	CHN	1	0	0%
Xu et al.	CHN	1	0	0%
Anderson et al.	Tennessee, USA	1	0	0%
Bao et al.	CHN	1	0	0%
Cinar et al.	TUR	1	0	0%
Kong et al.	CHN	1	0	0%
Hueso et al.	FRA	16	1	6%
Hartman et al.	Wisconsin, USA	27	4	13%
Jamous et al.	South Dakota, USA	24	5	17%
Olivares-Gazca et al.	MEX	8	2	20%
Tremblay et al.	New York, USA	14	10	42%
Case Series or Reports Total		132	22	14%

Figure legend

Figure 1. The impact of human convalescent plasma therapy on COVID-19 patient mortality. Forest plot illustrating odds ratios and 95% confidence intervals computed for each clinical study and pooled for each study type (DerSimonian–Laird random-effects model). Data are separated by study type with randomized clinical trials presented in blue and matched-control studies presented in orange. Odds ratios for each study type are presented in darker hues and the overall odds ratio pooled across all clinical studies is presented in green. The 95% confidence interval upper limit for Zeng et al. was 6.85.

Figure 1

Supplemental Table 1 | Descriptive Data for Convalescent Plasma Studies

	Convalescent Plasma							Control			
	n	Women (%)	Age (years)	Mechanical Ventilation (%)	Antibody Inclusion Threshold	Plasma Volume (mL)	Follow-up (days)	n	Women (%)	Age (years)	Mechanical Ventilation (%)
Randomized Clinical Trials											
Avendano-Sola et al.	38	47	61	0	No	250-300	29	43	44	60	0
Rasheed et al.	21	43	56	81	Yes (ELISA IgG index >1.25)	≥ ~200	30	28	43	48	57
Gharbharan et al.	43	33	63	19	Yes (neutralizing antibody titer ≥1:80)	≥ 300	30	43	23	61	12
Li et al.	52	48	70	27	Yes (neutralizing antibody titer ≥1:640)	200	28	51	35	69	22
Agarwal et al.	235	25	52	8	No	400	28	229	23	52	9
Matched-Control Studies											
Duan et al.	10	40	53	30	Yes (neutralizing antibody titer ≥1:640)	200	-	10	40	53	-
Perotti et al.	46	39	63	15	Yes (neutralizing antibody titer ≥1:80)	≥ 250	7	23	-	-	-
Omrani et al.	40	15	48	20	No	400	28	40	12	56	30
Hegerova et al.	20	-	60	35	No	≥ ~200	14	20	-	-	-
Zeng et al.	6	17	62	83	No	≥ 200	-	15	27	73	87
Donato et al.	47	53	59	6	Yes (neutralizing antibody titer ≥1:500)	≥ 200	30	1340	-	-	-
Salazar et al. (ARG)	868	31	56	21	Yes (ELISA IgG index >1350)	200-250	28	2298	33	64	22
Liu et al.	39	36	55	10	Yes (ELISA IgG titers ≥1:320)	500	14	156	29	54	-
Salazar et al. (USA)	321	43	53	5	Yes (ELISA IgG index >1350)	≥ ~200	60	582	44	60	5
Xia et al.	138	44	65	1	No	≥ ~200	14	1430	50	63	0.2
Abolghasemi et al.	115	42	54	0	Yes (ELISA IgG index >1.1)	≥ 500	30	74	50	57	0
Rogers et al.	64	42	61	11	No	≥ ~200	28	177	46	61	12
Altuntas et al.	888	31	60	49	No	200-600	17	888	29	61	55
Case Series or Reports											
Martinez-Resendez et al.	8	25	57	63	Yes (ELISA IgG titers > 1:100)	500	23				
Jin et al.	6	33	61	50	Yes (neutralizing antibody titer ≥1:40)	200	60				
Ye et al.	6	50	58	0	No	≥ 200	25				
Shen et al.	5	40	65	100	Yes (neutralizing antibody titer ≥1:40)	400	47				
Zhang et al.	4	50	57	100	No	≥ ~200	38				
Ahn et al.	2	50	69	100	No	250	15				
Bobek et al. [a]	2	-	-	-	Yes (-)	600	14				
Jin et al.	3	0	24	0	No	400	31				
Im et al.	1	0	68	100	No	500	23				
Peng et al.	1	100	66	100	Yes (ELISA IgG titers > 1:160)	400	26				
Xu et al.	1	0	65	100	No	800	11				
Anderson et al.	1	100	35	0	No	~400	10				
Bao et al.	1	0	38	100	No	300	31				
Cinar et al.	1	0	55	0	Yes (ELISA IgG index >1.1)	350	11				
Kong et al.	1	0	100	0	Yes (neutralizing antibody titer ≥1:640)	300	13				
Heueso et al.	17	71	58	12	Yes (neutralizing antibody titer ≥1:40)	800	7				
Hartman et al.	31	32	-	32	No	≥ ~200	7				
Jamous et al.	29	24	58	68	No	~200	28				
Olivares-Gazca et al.	10	0	52	50	No	≥ ~200	8				
Tremblay et al.	24	42	69	13	Yes (ELISA IgG titers > 1:320)	500	9				

[a] Only abstract available for Bobek et al.

-, data unavailable

Supplemental Table 2 | Relative Study Weights for Random Effects Models	
Model	**Relative Weight (%)**
Randomized Clinical Trials – Random-effects Model	
Avendano-Sola et al.	5
Rasheed et al.	8
Gharbharan et al.	22
Li et al.	25
Agarwal et al.	40
Randomized Clinical Trials – Random-effects Model [a]	
Avendano-Sola et al.	5
Rasheed et al.	10
Gharbharan et al.	38
Li et al.	47
Matched-Control Studies – Random-effects Model	
Duan et al.	1
Perotti et al.	3
Omrani et al.	2
Hegerova et al.	3
Zeng et al.	1
Donato et al.	10
Salazar et al. (ARG)	20
Liu et al.	6
Salazar et al. (US)	13
Xia et al.	5
Abolghasemi et al.	9
Rogers et al.	8
Altuntas et al.	19
Overall – Random-effects Model [a]	
Avendano-Sola et al.	1
Rasheed et al.	2
Gharbharan et al.	5
Li et al.	5
Duan et al.	1
Perotti et al.	3
Omrani et al.	1
Hegerova et al.	2
Zeng et al.	1
Donato et al.	9
Salazar et al. (ARG)	18
Liu et al.	5
Salazar et al. (US)	11
Xia et al.	4
Abolghasemi et al.	8
Rogers et al.	7
Altuntas et al.	17

[a] Random-effects model excludes trial by Agarwal et al.